Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multistage nanomedicine engineering to overcome sequential barriers to glioblastoma treatment: a review.

Journal of nanobiotechnology·2026
Same author

Unveiling a Hidden Conversion Pathway in CoSe<sub>2</sub> Anodes via Rationally Designed CNT-Interwoven Hollow Carbon Microclusters for High-Performance Potassium-Ion Batteries.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Incidence of Bacille Calmette-Guérin associated lymphadenitis in healthy children: A systematic review and meta-analysis.

Human vaccines & immunotherapeutics·2026
Same author

Stimuli-Responsive Zirconium-Based Metal-Organic Frameworks for Targeted Cancer Drug Delivery.

ACS applied materials & interfaces·2026
Same author

Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.

Human vaccines & immunotherapeutics·2026
Same author

Corrosion-Inspired Stabilization of Cobalt Oxide Catalysts via Platinum-Mediated Redox Buffering for Proton Exchange Membrane Water Electrolysis.

Advanced materials (Deerfield Beach, Fla.)·2026

Related Experiment Video

Updated: May 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Nucleic acid scavengers inhibit thrombosis without increasing bleeding.

Shashank Jain1, George A Pitoc, Eda K Holl

  • 1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Proceedings of the National Academy of Sciences of the United States of America
|July 28, 2012
PubMed
Summary

Nucleic acid-binding polymers show promise as safer antithrombotic agents. These polymers scavenge prothrombotic molecules, preventing blood clots without increasing bleeding risk in preclinical models.

More Related Videos

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Experiment Videos

Last Updated: May 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Area of Science:

  • Biochemistry
  • Pharmacology
  • Vascular Biology

Background:

  • Developing safe antithrombotic agents is challenging due to increased bleeding risk.
  • Naturally occurring polyphosphates like DNA, RNA, and inorganic polyphosphates activate blood coagulation.
  • Existing anticoagulants carry a significant risk of hemorrhage.

Purpose of the Study:

  • To evaluate the anticoagulant and antithrombotic potential of nucleic acid-binding polymers.
  • To determine if these polymers can inhibit polyphosphate-induced coagulation.
  • To assess the safety and efficacy of these agents in preclinical thrombosis models.

Main Methods:

  • In vitro assessment of polymer inhibition of RNA- and polyphosphate-induced clotting.
  • Evaluation of polymer effects on the intrinsic pathway of coagulation.
  • In vivo studies using mouse models of carotid artery injury and pulmonary thromboembolism.

Main Results:

  • Nucleic acid-binding polymers effectively inhibited RNA- and polyphosphate-induced clotting in vitro.
  • PAMAM G-3 demonstrated significant antithrombotic activity in mouse models.
  • No significant increase in blood loss was observed in treated animals, indicating a favorable safety profile.

Conclusions:

  • Nucleic acid-binding polymers can effectively scavenge prothrombotic nucleic acids and polyphosphates in vivo.
  • These polymers represent a novel class of antithrombotic agents with potentially improved safety.
  • Further research into nucleic acid-binding polymers could lead to safer treatments for thrombotic disorders.